ESR1 and breast neoplasm: In addition, Luclie et al.31 has stated that patients treated with paclitaxel appeared to be more at risk of developing persistent clinically significant CIPN especially if they were older than 75 and other potential factors were insignificant as regards being an ER positive or negative breast tumor.